Assessment of Novel Therapeutics to Improve Access to Transplantation for Highly Sensitized Patients in a Shifting Clinical Landscape-Reference-Cited by-同舟云学术

Assessment of Novel Therapeutics to Improve Access to Transplantation for Highly Sensitized Patients in a Shifting Clinical Landscape

Published:2024-03 Issue:3 Volume:35 Page:259-260
ISSN:1046-6673
Container-title:Journal of the American Society of Nephrology
language:en
Short-container-title:JASN

Author:

Lan James H.¹^ORCID

Affiliation:

1. British Columbia Provincial Immunology Laboratory, Vancouver Coastal Health, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; and Division of Nephrology, Kidney Transplant Program, University of British Columbia, Vancouver, British Columbia, Canada

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference11 articles.

1. Isatuximab monotherapy for desensitization in highly sensitized patients awaiting kidney transplant;Vincenti;J Am Soc Nephrol.,2024

2. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow;Halliley;Immunity.,2015

3. Prospective iterative trial of proteasome inhibitor-based desensitization;Woodle;Am J Transplant.,2015

4. A prospective, iterative, adaptive trial of carfilzomib-based desensitization;Tremblay;Am J Transplant.,2020

5. Humoral compensation after bortezomib treatment of allosensitized recipients;Kwun;J Am Soc Nephrol.,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical relevance of HLA-DQ eplet mismatch and maintenance immunosuppression with risk of allosensitization after kidney transplant failure;Frontiers in Genetics;2024-04-04